Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact Us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
24: Making big ideas investible and measuring impact | Dan Somers of Boundary Capital
Stay up-to-date with the latest research
Sign up to our newsletter
COVID-19: -
Our Commitment to Client Service & Investor Communications
Life Sciences research
Diurnal Group Plc
Life Sciences
$52.5m US deal strengthens balance sheet further
By
Dr Martin Hall
30 Mar 2020
Arix Bioscience
Life Sciences
Fiscal 2019 – moving with the times
By
Dr Dorothea Hill
19 Mar 2020
Stay up-to-date with the latest research
Sign up to our newsletter
Allergy Therapeutics plc
Life Sciences
Consistent first-half revenue growth
By
Dr Martin Hall
09 Mar 2020
Shield Therapeutics Plc
Life Sciences
March 2020 Investor Forum
By
Dr Martin Hall
06 Mar 2020
Diurnal Group Plc
Life Sciences
… and more to come (news flow)
By
Dr Gregoire Pave
28 Feb 2020
Arix Bioscience
Life Sciences
With high risk can come high reward
By
Dr Dorothea Hill
19 Feb 2020
Advanced Oncotherapy
Life Sciences
Confidence in LIGHT gaining momentum
By
Dr Martin Hall
17 Feb 2020
Tissue Regenix
Life Sciences
Restructured to satisfy product demand
By
Dr Dorothea Hill
06 Feb 2020
genedrive Plc
Life Sciences
Western market progress but developing markets difficult
By
Dr Dorothea Hill
05 Feb 2020
Shield Therapeutics Plc
Life Sciences
Good demand for Feraccru in Europe
By
Dr Martin Hall
28 Jan 2020
Allergy Therapeutics plc
Life Sciences
Sales growth well above market average
By
Dr Martin Hall
16 Jan 2020
Prev
1
2
3
4
5
...
17
Next
